| Baseline (all participants, n = 30) | Baseline (of participants followed-up, n = 16) | 6 months (n = 16) |
---|---|---|---|
CORE-OM Total score | |||
 Mean (SD) | 21.0 (5.73) | 20.2 (5.92) | 16.9 (8.27) |
 95% CI | (18.83 to 23.10) |  | (12.54 to 21.36) |
 Range | 12.4 to 33.5 | 12 to 32 | 5.9 to 29.7 |
CORE-OM Categories | |||
 Clinical (10 to 40) | 30 (100.0%) | 16 (100.0%) | 12 (75.0%) |
 Non-clinical (Less than 10) | 0 (0.0%) | 0 (0.0%) | 4 (25.0%) |
Reliable and clinically significant improvement (RCSI) on CORE-OM | Â | Â | 0 (0.0%) |
CORE-OM total change from baseline | |||
 Mean (SD) |  |  |  − 3.2 (5.44) |
 95% CI |  |  | (− 6.13 to − 0.34) |
 Range |  |  |  − 11.5 to 7.4 |
Beck Hopelessness Scale total score | |||
 Mean (SD) | 14.4 (4.80) | 13.3 (4.70) | 10.6 (6.41) |
 95% CI | (12.60 to 16.18) |  | (7.16 to 14.00) |
 Range | 3.0 to 20.0 | 4.0 to 20.0 | 1.0 to 20.0 |
PHQ-9 | |||
 Mean (SD) | 18.7 (5.23) | 18.6 (5.49) | 14.4 (7.90) |
 95% CI | (16.76 to 20.67) |  | (9.80 to 18.92) |
 Range | 9.0 to 26.0 | 9.0 to 26.0 | 2.0 to 27.0 |
SCS-R | |||
 Mean (SD) | 59.2 (17.68) | 59.0 (15.45) | 66.3 (23.74) |
 95% CI | (52.56 to 65.77) |  | (53.66 to 78.96) |
 Range | 22.0 to 101.0 | 35.0 to 90.0 | 28.0 to 99.0 |